

## REMARKS

The Examiner has required restriction to one of the following inventions is required under 35 U.S.C. 121 and 372:

Group 1. Claims 1-5, and 11-13, drawn to a method of treating osteoarthritis comprising: administering, to a subject suffering from a osteoarthritis, a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of an anti-IL-6 receptor antibody.


Group 2. Claims 1-2, and 6-13, drawn to a method of treating osteoarthritis comprising: administering, to a subject suffering from a osteoarthritis, a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of an anti-IL-6 antibody.

Applicants elect the invention of Group 2 (Claims 1-2, and 6-13). Applicants reserve the right to file one or more divisional or continuation applications directed to non-elected subject matter.

Applicant has amended claim 1 to remove the non-elected subject matter. Claim 13 has been amended as suggested by the Examiner.

Applicants submit that the present invention is now in condition for allowance. Early allowance of all pending claims is respectfully solicited.

Respectfully submitted,



S. Christopher Bauer  
Registration No. 42,305  
TEL: 314-274-6257

Pfizer Inc  
P. O. Box 1027  
St. Louis, MO 63006